You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.
Our Acrodose™ Systems are closed systems for the pooling, storage, and bacteria testing of leukoreduced whole blood-derived platelet concentrates. With Acrodose Systems, your center can now provide a new generation platelet product — an Acrodose Platelet — that offers you a real alternative to optimize the availability, safety, and cost of transfusion platelets. We offer the following two Acrodose Systems for maximum flexibility:
*Equivalent therapeutic dose in terms of platelet count and quality.
Our Acrodose Systems help you make use of the abundant, but often discarded, resources of whole blood platelets that are more readily available than apheresis platelets. This helps to increase your product availability with fewer product shortages, and less need to import, and enhances your center’s overall growth.
An Acrodose™ Platelet is “transfusion ready” and provides both the blood centers and clinicians with significant benefits over single donor and whole blood platelet products:
Significantly increases platelet availability
Relying solely on single donor platelets can lead to product shortages and require costly importing, resulting in lower margins for the blood center and creating strain on the hospital to meet patient demands.
Utilizes an untapped resource
Whole blood platelets are an available resource, unnecessarily discarded every day. An Acrodose Platelet utilizes this resource and allows blood
collection facilities to increase platelet availability while also providing the opportunity to export.
Takes advantage of blood center growth opportunities
Because of their abundant supply and low cost, the production of a therapeutic dose of whole blood platelets offers an untapped growth opportunity for blood centers.
Lowers hospital handling costs
An Acrodose Platelet is received at the hospital pre-pooled and tested via a U.S. FDA market-cleared device for platelet bacteria detection.
Hospitals no longer have to test whole blood platelets with less sensitive methods such as dipsticks and pH meters, which have a higher probability of false negatives (increasing liability exposure) and false positives (increasing cost).
Reduces the per-unit risk attributed to antibody-mediated TRALI (Transfusion Related Acute Lung Infection)
An Acrodose Platelet is comprised of whole blood-derived platelets and may be a better alternative when considering the risks associated with antibody-mediated TRALI*.
*Whole blood platelets are defined within AABB bulletin 06-07 as a “lower plasma volume component”, and “the per-unit risk attributed to antibody-mediated TRALI from [this] component appears to be significantly lower” than single donor platelets.
Two Approaches to Making an Acrodose™ Platelet
Using a platform of complementary products, your center can produce a therapeutic dose of whole blood-derived platelets that are leukoreduced, ABO-matched, pooled, and bacteria tested with culture-based detection methods — in other words, an Acrodose Platelet.
*Customer may use an alternative market-cleared bacteria detection system.
For Acrodose PL System with attached eBDS™ Sample Set (Reorder Code: 732-80)
For Acrodose PLus System with attached eBDS Sample Set (Reorder Code: 732-82)
For Acrodose PLus System (Reorder Code: 732-83)
For Acrodose PL System (Reorder Code: 732-86)
© 2011-2017 Haemonetics Corporation • 400 Wood Road • Braintree • MA • 02184